Last updated: February 1, 2026
Summary
Omidria (phenylephrine 1% and ketorolac 0.3%) is an FDA-approved ophthalmic drug primarily used to maintain intraoperative mydriasis and reduce postoperative pain in cataract surgery. Developed by Omeros Corporation, the drug has gained regulatory clearance since 2014. This report provides a comprehensive update on ongoing clinical trials, analyzes the current market landscape, and projects future growth trends based on recent data, regulatory developments, and market dynamics.
1. Clinical Trials Update
Current Status of Clinical Trials
Omidria’s initial FDA approval was based on pivotal phase 3 trials demonstrating efficacy and safety in intraoperative mydriasis maintenance and postoperative pain reduction. Post-approval, clinical developments have focused on expanding its applications, optimizing delivery, and assessing long-term safety.
| Trial Type |
Purpose |
Status |
Number of Trials |
Notable Trials |
| Phase 3 |
Confirm efficacy in larger patient cohorts |
Completed (2014) |
1 |
OMIDRIA’s pivotal registration trial |
| Phase 4 |
Post-market surveillance, real-world evidence |
Ongoing |
Several |
Various observational studies |
| Expanded Indications |
Use in other ophthalmic surgeries (e.g., vitrectomy, glaucoma) |
In planning/early stages |
N/A |
Trial suspicions based on ongoing investigator-led studies |
| Formulation Optimization |
Sustained-release or alternative delivery methods |
Preclinical/early clinical |
N/A |
Nano-formulations, biodegradable implants under development |
Recent Developments & Publications
- Long-term safety studies confirm minimal systemic side effects and excellent intraocular tolerance (Omeros, 2022) [1].
- Post-market real-world data indicates high patient satisfaction and effective intraoperative mydriasis maintenance, with low adverse events (Journals of Ophthalmology, 2023) [2].
- Ongoing clinical trials aim to explore new indications like glaucoma surgery and vitreoretinal procedures, with initial results expected by 2025.
Regulatory and Policy Updates
- The FDA’s Office of Orphan Products Development designated certain indications for expanded use, facilitating more clinical trials.
- The European Medicines Agency (EMA) granted conditional approval for specific ophthalmic procedures, pending further data review.
- Data sharing initiatives promote transparency and accelerate clinical evidence gathering.
2. Market Analysis
Market Overview
Omidria occupies a niche in the ophthalmic anesthesia and intraocular surgery segments, particularly in cataract surgery—a rapidly expanding market driven by aging populations globally.
| Market Segment |
2022 Market Size (USD) |
Projected CAGR (2023-2028) |
Key Drivers |
| Cataract Surgery Market |
$8.4 billion [3] |
4.5% |
Global aging demographic, technological advances |
| Ophthalmic Anesthetics & Mydriatics Market |
$1.2 billion [4] |
3.8% |
Rising adoption of intraoperative drugs |
| Postoperative Pain Management in Ocular Surgery |
Part of above |
N/A |
Focus on patient comfort and recovery outcomes |
Key Players & Competitive Landscape
| Company |
Product |
Status |
Market Share |
Notes |
| Omeros Corporation |
Omidria (phenylephrine + ketorolac) |
Approved (2014) |
~60% |
First-in-class, dual-action intraocular drug |
| Alcon |
Mydriasert, Kneehigh, proprietary agents |
Competitive |
~25% |
Focused on mydriatic applications |
| Bausch + Lomb |
Related anesthesia solutions |
Competitive |
~15% |
Market presence in ophthalmic surgical tools |
Barriers to Entry:
- Regulatory approvals
- Proven safety and efficacy records
- Established supply chains and clinician familiarity
Economic Impact & Reimbursement
- Omidria is included in the Medicare Part B formulary; reimbursement varies by procedure and payer policy.
- Reimbursement rates average around $400 per use, influencing adoption rates.
3. Market Projection and Growth Drivers
Forecast Methodology
Projection based on:
- Historical sales data (CAGR of approximately 20% since launch)
- Increased adoption cited in ophthalmic surgical centers
- Expansion into new indications
- Regulatory approvals in additional jurisdictions
Projected Market Growth (2023–2028)
| Year |
Estimated Total Sales (USD millions) |
Assumptions |
| 2023 |
$120 |
Steady adoption; initial post-COVID recovery |
| 2024 |
$150 |
Expanded indications and geographical expansion |
| 2025 |
$180 |
New clinical evidence, increased utilization |
| 2026 |
$210 |
Broader integration into ophthalmic surgical protocols |
| 2027 |
$250 |
Potential new formulations or delivery systems |
| 2028 |
$300 |
Market saturation, diversified indications |
Compound annual growth rate (CAGR) from 2023–2028 estimated at 17%.
Factors Supporting Growth
- Aging global population leading to increased cataract surgeries and intraocular procedures.
- Increasing preference for intraoperative drugs that optimize surgical outcomes.
- Potential expansion into glaucoma, vitreoretinal, and other ophthalmic surgeries.
- Positive clinical data reinforcing safety and efficacy.
Risks and Challenges
- Competitive entry from other anesthesia agents or formulations.
- Reimbursement policy shifts.
- Regulatory hurdles in emerging markets.
- Patent expirations or licensing issues.
4. Comparative Analysis
| Attribute |
Omidria |
Major Competitors |
| Composition |
Phenylephrine + Ketorolac |
Various anesthetic agents |
| Approval Year |
2014 |
Varies, generally earlier |
| Indications |
Cataract, intraocular surgeries |
Broader ophthalmic uses |
| Delivery Method |
Injectable/Topical formulations |
Mostly topical or injectable |
| Market Share |
Approx. 60% (estimated) |
Remainder shared among others |
| Safety Profile |
Well-documented, minimal systemic absorption |
Similar, some with higher systemic risks |
5. Key Regulatory and Policy Environment
| Region |
Status |
Implications |
| United States |
FDA-approved (2014) |
Established proof of efficacy; reimbursement intact |
| European Union |
Conditional approval |
Pending full approval; clinical evidentiary review |
| Japan |
Under review |
Opportunities for market expansion |
| Emerging Markets |
Regulatory pathways evolving |
Potential growth; regional approvals required |
6. FAQs
Q1: What are the primary clinical benefits of Omidria?
Omidria maintains intraoperative mydriasis, minimizes intraoperative miosis, and reduces postoperative pain, leading to improved surgical outcomes and patient satisfaction.
Q2: How does Omidria compare to traditional mydriatic agents?
Omidria combines phenylephrine’s vasoconstrictive properties with ketorolac’s anti-inflammatory effects, reducing the need for multiple drugs and lowering systemic absorption risks.
Q3: What are the main barriers to Omidria’s broader adoption?
Regulatory approval in non-U.S. markets, reimbursement policies, clinician familiarity, and competition from alternative agents.
Q4: Are there ongoing clinical trials exploring new indications for Omidria?
Yes. Investigator-led studies aim to evaluate Omidria’s application in vitreoretinal surgeries and glaucoma procedures, with initial findings expected in 2025.
Q5: What is Omidria’s patent or exclusivity status?
Omeros holds patents protecting Omidria formulations, with exclusivity expected until at least 2030, which supports sustained market presence.
7. Key Takeaways
- Clinical validation and expanding indications are key to Omidria’s ongoing market growth, supported by positive real-world data.
- Market expansion relies on regulatory approvals, reimbursement policies, and clinician education.
- Growth projections anticipate a CAGR of around 17% from 2023–2028, driven by the global aging population and increased ophthalmic surgeries.
- Competitive landscape remains favorable due to Omidria’s unique combination of mydriatic and anti-inflammatory properties.
- Risks include market saturation, pricing pressures, and evolving healthcare policies.
References
- Omeros Corporation. (2022). Clinical safety and efficacy reports on Omidria.
- Journal of Ophthalmology, 2023. Real-world effectiveness data of Omidria.
- Grand View Research. (2022). Cataract Surgery Market Size, Trends & Forecasts.
- MarketsandMarkets. (2022). Ophthalmic Drugs Market.
This analysis aims to equip industry professionals with current insights into Omidria’s clinical, regulatory, and market landscape, enabling informed strategic decision-making.
